The leading source for credible citizen reporting

Report Your News
Take the tour...

This event is older than two months and is no longer active. Some links older than two months could be broken.

Report Your News

Click here to post a new related report

Scientific American: The Orphan Drug Backlash

Palo Alto : CA : USA | 2 months ago  
Views: 12
In June 1989 Amgen, a small biotechnology company in Thousand Oaks, Calif., gained U.S. Food and Drug Administration approval to market its first product, epoetin alfa (Epogen), to treat the anemia that accompanies end-stage kidney failure.
  • Print
  • Share:
  • Share
  • Digg
  • Reddit
  • Facebook
  • Stumbleupon

Related Allvoices Contributions

News Stories
 
  • News Source: Androscoggin News | 2 months ago
    The difference in PFS correlated with a median survival of 16.8 months in the maintenance group vs...About Telik Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to...
  • News Source: Uinta County News | 2 months ago
    In June 1989 Amgen, a small biotechnology company in Thousand Oaks, Calif., gained U.S. Food and Drug Administration approval to market its first product, epoetin alfa (Epogen), to treat the anemia that accompanies end-stage kidney failure.
Most Popular Reports

Related Allvoices Reports

Contributions

Help and Accounts


Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc 2008-2009. All rights reserved.